Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study

Clopidogrel is an antiplatelet drug that is prescribed after percutaneous coronary intervention (PCI) to prevent stent thrombosis. Previous studies have suggested that some statins may inhibit the antiplatelet effects of clopidogrel via competitive metabolism of its activating enzyme cytochrome P450 3A4 (CYP3A4).

[1]  Samy Suissa,et al.  Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages , 2007, Nature Clinical Practice Rheumatology.

[2]  S. Kaul,et al.  Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease , 2007, Annals of Internal Medicine.

[3]  James A Hanley,et al.  Do Oscar Winners Live Longer than Less Successful Peers? A Reanalysis of the Evidence , 2006, Annals of Internal Medicine.

[4]  J. Brophy,et al.  A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. , 2006, American heart journal.

[5]  M. Bottorff,et al.  Statin safety and drug interactions: clinical implications. , 2006, The American journal of cardiology.

[6]  H. Guess.  Exposure‐time‐varying hazard function ratios in case‐control studies of drug effects , 2006, Pharmacoepidemiology and drug safety.

[7]  J. Brophy,et al.  The benefit of cholesterol-lowering medications after coronary revascularization: a population study. , 2005, American heart journal.

[8]  K. Eagle,et al.  Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. , 2005, European heart journal.

[9]  K. Eagle,et al.  Wire artefact—in reverse! , 2004, Heart.

[10]  R. Paoletti,et al.  Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions , 2004, Circulation.

[11]  R. Tamblyn,et al.  Validation of diagnostic codes within medical services claims. , 2004, Journal of clinical epidemiology.

[12]  A. Mrhar,et al.  Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. , 2003, International journal of clinical pharmacology and therapeutics.

[13]  J. Brophy,et al.  The use of cholesterol-lowering medications after coronary revascularization. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  M. Spiecker,et al.  Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. , 2003, European heart journal.

[15]  S. Steinhubl,et al.  Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial , 2003, Circulation.

[16]  T. Heer,et al.  Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. , 2003, The American journal of cardiology.

[17]  Lawrence Joseph,et al.  Evidence for use of coronary stents: a hierarchical bayesian meta-analysis ☆ , 2003 .

[18]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[19]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[20]  Deepak L. Bhatt,et al.  Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. , 2002, Journal of the American College of Cardiology.

[21]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[22]  Per Kragh Andersen,et al.  Modern Epidemiology. 2nd edn. Kenneth J. Rothman and Sander Greenland, Lippincott‐Raven, U.S.A., 1998. No. of pages: 737. Price: $74.50. ISBN 0‐316‐75780‐2 , 2000 .

[23]  A R Levy,et al.  Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. , 1999, The Canadian journal of cardiology.

[24]  R. Califf,et al.  Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. , 1999, The New England journal of medicine.

[25]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[26]  Nathan Mantel,et al.  Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .

[27]  B. Gersh.  Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial , 2008 .

[28]  S. Suissa.  Practice of Epidemiology Immortal Time Bias in Pharmacoepidemiology , 2008 .

[29]  L. Waskell,et al.  The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[30]  A. Kastrati,et al.  A RANDOMIZED COMPARISON OF ANTIPLATELET THERAPY AFTER THE PLACEMENT OF CORONARY ARTERY STENTS , 1996 .

[31]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .